Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform develops first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea, which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.